Is Acyclovir Hepatotoxic?
Acyclovir is not considered hepatotoxic and hepatotoxicity is not a recognized adverse effect of this medication. The primary toxicities associated with acyclovir are nephrotoxicity (through renal tubular crystallization) and neurotoxicity, not liver injury.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for acyclovir does not list hepatotoxicity as an adverse effect 1. The primary safety concerns emphasized in the drug label are:
- Renal dysfunction requiring dosage adjustment in patients with renal impairment
- Reversible central nervous system symptoms (agitation, coma, seizures, lethargy)
- Precipitation in renal tubules when solubility is exceeded
- Local inflammation and phlebitis at injection sites with IV administration
The label specifically warns about nephrotoxicity and CNS effects but makes no mention of hepatotoxicity as a concern 1.
Supporting Clinical Evidence
Multiple sources confirm acyclovir's safety profile regarding the liver:
Clinical trial data from 1987 showed that acyclovir administered at 45 mg/kg/day as continuous IV infusion for 28 days in chronic hepatitis B patients resulted in "no significant adverse effects of therapy" 2. This high-dose, prolonged exposure study would have detected hepatotoxicity if it were a significant concern.
A comprehensive 1988 review of adverse reactions to acyclovir identified the most frequent serious adverse effects as: (1) encephalopathic changes and (2) renal precipitation of the drug—with no mention of hepatotoxicity 3.
Recent mechanistic research (2026) on acyclovir toxicity focuses exclusively on nephrotoxicity and neurotoxicity, attributing these to acyclovir metabolites (particularly CMMG for neurotoxicity and acyclovir aldehyde for nephrotoxicity), with no discussion of hepatic effects 4.
Context: Hepatotoxicity in Azathioprine (Not Acyclovir)
The provided guidelines discussing hepatotoxicity relate to azathioprine, not acyclovir 5. These guidelines mention acyclovir only in the context of treating varicella zoster infections in immunosuppressed patients, not as a hepatotoxic agent. This is an important distinction—azathioprine causes hepatotoxicity; acyclovir does not.
Clinical Implications
When prescribing acyclovir, monitor for:
- Renal function (BUN, creatinine)—the primary concern
- Adequate hydration to prevent crystalluria
- CNS symptoms (confusion, tremors, seizures), particularly in elderly patients or those with renal impairment
- CMMG levels if neurotoxicity is suspected (>10 µmol/mL in serum or >1 µmol/mL in CSF) 4, 6
Routine liver function monitoring is not indicated when using acyclovir, as hepatotoxicity is not an established adverse effect of this medication.